All In Biotech

NDA 211230 · Axsome Malta

Sunosi

Solriamfetol Hydrochloride · Oral · Dopamine and Norepinephrine Reuptake Inhibitor

NovelOrphan

Last checked: Nov 20, 2026Latest source record: Jun 28, 2023 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2019

Mar 20, 2019

Approved uses

2

Original approval plus efficacy supplements

Registered trials

31

15 Phase 3, 8 recruiting

FAERS reports

3,852

1,607 serious, 14 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect May 5, 2026.

SUNOSI is indicated to improve wakefulness in adult patients with excessive daytime sleepiness associated with narcolepsy or obstructive sleep apnea (OSA) [see Clinical Studies ( 14 )] . Limitations of Use SUNOSI is not indicated to treat the underlying airway obstruction in OSA. Ensure that the underlying airway obstruction is treated (e.g., with continuous positive airway pressure (CPAP)) for at least one month prior to initiating SUNOSI for excessive daytime sleepiness. Modalities to treat the underlying airway obstruction should be continued during treatment with SUNOSI. SUNOSI is not a substitute for these modalities. SUNOSI is a dopamine and norepinephrine reuptake inhibitor (DNRI) indicated to improve wakefulness in adult patients with excessive daytime sleepiness associated with narcolepsy or obstructive sleep apnea (OSA). ( 1 ) Limitations of Use SUNOSI is not indicated to treat the underlying airway obstruction in OSA. Ensure that the underlying airway obstruction is treated (e.g., with continuous positive airway pressure (CPAP)) for at least one month prior to initiating SUNOSI for excessive daytime sleepiness. Modalities to treat the underlying airway obstruction should be continued during treatment with SUNOSI. SUNOSI is not a substitute for these modalities. ( 1 )

Mechanism: The mechanism of action of solriamfetol to improve wakefulness in patients with excessive daytime sleepiness associated with narcolepsy or obstructive sleep apnea is unclear. However, its efficacy could be mediated through its activity as a dopamine and norepinephrine reuptake inhibitor (DNRI).

Therapeutic areas: Kidney and urology

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

2 products under this application
  • SUNOSI · SOLRIAMFETOL HYDROCHLORIDE EQ 75MG BASE · TABLET, ORAL · Prescription · TE AB
  • SUNOSI · SOLRIAMFETOL HYDROCHLORIDE EQ 150MG BASE · TABLET, ORAL · Prescription · TE AB

Clinical trials

Interventional ClinicalTrials.gov studies with "Solriamfetol" as an intervention, any sponsor and status, largest first.

All 31 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • drug ineffective541
  • anxiety343
  • headache320
  • nausea307
  • fatigue275
  • product administration interrupted272
  • somnolence255
  • off label use253
  • product dose omission issue201
  • surgery180
  • dizziness173
  • depression168

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20157
201623
201720
20189
2019105
2020535
2021532
2022800
2023564
2024599
2025429
2026229

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Sunosi (Solriamfetol HCl)

2024 spending

$21.0M

Beneficiaries

4,007

20,031 claims

Per beneficiary

$5,247

$28.56 per unit

View as table
YearSpending
2020$4,965,429
2021$10,241,349
2022$13,749,335
2023$17,479,999
2024$21,025,661

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 40 on PubMed

Sponsor: Axsome Malta

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.